Psychiatry AdvisorQuetiapine Plus CBT Reduces Suicide Risk in Adults with Mood Disorders

A 12-week randomized trial of 148 adults with mood disorders found that adding CBT to quetiapine cut the proportion of high-suicide-risk patients nearly in half compared to quetiapine alone (13.4% vs 30.0%). Combined therapy also produced 6.5-point greater HDRS-24 improvement and significantly better positive coping scores.

🧠 Clinical Considerations

• High suicide risk dropped from 45.7% to 13.4% in the combination group versus 45.7% to 30.0% with quetiapine monotherapy, a statistically significant between-group difference (P=.02).
• Depressive symptom reduction was nearly double with combined therapy: HDRS-24 dropped 12.5 points with quetiapine plus CBT versus 7.4 points with quetiapine alone.
• Maladaptive coping scores improved significantly with combined therapy, addressing a behavioral mechanism directly tied to suicide risk escalation.
• Single-center design and 12-week follow-up limit generalizability; long-term durability of suicide risk reduction remains unstudied.

🎯 Practice Applications

• Integrate structured CBT referrals into quetiapine treatment plans for mood disorder patients with elevated suicide risk.
• Screen all mood disorder patients using a validated suicide risk tool at baseline and regularly throughout treatment.
• Document coping style assessment alongside symptom severity to track combined therapy response.
• Advocate for expanded psychology staffing in your practice or health system to support adjunctive psychotherapy access.

More in CBT